{"id":43442,"date":"2025-10-15T16:45:45","date_gmt":"2025-10-15T08:45:45","guid":{"rendered":"https:\/\/flcube.com\/?p=43442"},"modified":"2025-10-15T16:45:45","modified_gmt":"2025-10-15T08:45:45","slug":"eisai-biogen-secure-tga-approval-for-lecanemab-leqembi-in-early-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43442","title":{"rendered":"Eisai\u202f&amp;\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease"},"content":{"rendered":"\n<p>Japanese pharmaceutical giant <strong>Eisai Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4523:TYO\">TYO: 4523<\/a>) and U.S. biopharma <strong>Biogen Inc.<\/strong> (NASDAQ: BIIB) announced today that the <strong>Australian Therapeutic Goods Administration (TGA)<\/strong> has granted marketing approval for the humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 monoclonal antibody <strong>lecanemab<\/strong> (trade name <strong>Leqembi<\/strong>). The approval covers adult patients with <strong>mild cognitive impairment (MCI)<\/strong> or <strong>mild dementia<\/strong> attributable to <strong>Alzheimer\u2019s disease (AD)<\/strong> who are either <strong>non\u2011carriers<\/strong> or <strong>heterozygous carriers<\/strong> of the <strong>apolipoprotein\u202fE \u03b54 (ApoE\u03b54)<\/strong> allele.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-points\">Key Points<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Approval Scope<\/strong> \u2013 Leqembi is now authorized for early AD patients in Australia, expanding access beyond the U.S. and EU markets.<\/li>\n\n\n\n<li><strong>Patient Eligibility<\/strong> \u2013 Only patients who are non\u2011carriers or heterozygous carriers of ApoE\u03b54 may receive the drug; homozygous carriers remain excluded.<\/li>\n\n\n\n<li><strong>Regulatory Path<\/strong> \u2013 The decision follows a successful appeal by Eisai to the TGA\u2019s Administrative Review Tribunal after an initial denial in February\u202f2025.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-journey\">Regulatory Journey<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stage<\/th><th>Date<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td>Initial TGA Submission<\/td><td>2024<\/td><td>Not approved for early AD patients<\/td><\/tr><tr><td>Administrative Review Tribunal Appeal<\/td><td>March\u202f2025<\/td><td>Eisai\u2019s application reviewed<\/td><\/tr><tr><td>TGA\u2013Eisai Agreement<\/td><td>2025\u201110\u201114<\/td><td>Marketing approval granted<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The TGA\u2019s revised stance came after extensive discussions and a formal agreement between the agency and Eisai, enabling the drug\u2019s entry into the Australian market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Expansion<\/strong> \u2013 The approval positions Leqembi as a global option for early AD treatment, bolstering Eisai\u2019s pipeline in neurodegeneration.<\/li>\n\n\n\n<li><strong>Collaborative Advantage<\/strong> \u2013 The partnership with Biogen leverages the U.S. company\u2019s commercialization expertise and global distribution network.<\/li>\n\n\n\n<li><strong>Patient Access<\/strong> \u2013 Early AD patients in Australia can now receive a therapy that may slow disease progression, addressing a critical unmet need.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43444,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,350,993,1151],"class_list":["post-43442","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biogen","tag-eisai","tag-nasdaq-biib","tag-tyo-4523"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eisai\u202f&amp;\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing approval for the humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 monoclonal antibody lecanemab (trade name Leqembi). The approval covers adult patients with mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD) who are either non\u2011carriers or heterozygous carriers of the apolipoprotein\u202fE \u03b54 (ApoE\u03b54) allele.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43442\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai\u202f&amp;\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease\" \/>\n<meta property=\"og:description\" content=\"Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing approval for the humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 monoclonal antibody lecanemab (trade name Leqembi). The approval covers adult patients with mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD) who are either non\u2011carriers or heterozygous carriers of the apolipoprotein\u202fE \u03b54 (ApoE\u03b54) allele.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43442\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T08:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1512.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43442#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43442\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai\u202f&amp;\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease\",\"datePublished\":\"2025-10-15T08:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43442\"},\"wordCount\":296,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43442#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1512.webp\",\"keywords\":[\"Biogen\",\"Eisai\",\"NASDAQ: BIIB\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43442#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43442\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43442\",\"name\":\"Eisai\u202f&amp;\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43442#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43442#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1512.webp\",\"datePublished\":\"2025-10-15T08:45:45+00:00\",\"description\":\"Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing approval for the humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 monoclonal antibody lecanemab (trade name Leqembi). The approval covers adult patients with mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD) who are either non\u2011carriers or heterozygous carriers of the apolipoprotein\u202fE \u03b54 (ApoE\u03b54) allele.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43442#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43442\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43442#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1512.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1512.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eisai\u202f&\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43442#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai\u202f&amp;\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai\u202f&amp;\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing approval for the humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 monoclonal antibody lecanemab (trade name Leqembi). The approval covers adult patients with mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD) who are either non\u2011carriers or heterozygous carriers of the apolipoprotein\u202fE \u03b54 (ApoE\u03b54) allele.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43442","og_locale":"en_US","og_type":"article","og_title":"Eisai\u202f&amp;\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease","og_description":"Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing approval for the humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 monoclonal antibody lecanemab (trade name Leqembi). The approval covers adult patients with mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD) who are either non\u2011carriers or heterozygous carriers of the apolipoprotein\u202fE \u03b54 (ApoE\u03b54) allele.","og_url":"https:\/\/flcube.com\/?p=43442","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-15T08:45:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1512.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43442#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43442"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai\u202f&amp;\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease","datePublished":"2025-10-15T08:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43442"},"wordCount":296,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43442#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1512.webp","keywords":["Biogen","Eisai","NASDAQ: BIIB","TYO: 4523"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43442#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43442","url":"https:\/\/flcube.com\/?p=43442","name":"Eisai\u202f&amp;\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43442#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43442#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1512.webp","datePublished":"2025-10-15T08:45:45+00:00","description":"Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing approval for the humanized anti\u2011soluble aggregated amyloid\u2011\u03b2 monoclonal antibody lecanemab (trade name Leqembi). The approval covers adult patients with mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer\u2019s disease (AD) who are either non\u2011carriers or heterozygous carriers of the apolipoprotein\u202fE \u03b54 (ApoE\u03b54) allele.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43442#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43442"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43442#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1512.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1512.webp","width":1080,"height":608,"caption":"Eisai\u202f&\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43442#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai\u202f&amp;\u202fBiogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1512.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43442"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43442\/revisions"}],"predecessor-version":[{"id":43445,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43442\/revisions\/43445"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43444"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}